Concepedia

Safety and immunogenicity of the FINLAY-FR-1A vaccine in COVID-19 convalescent participants: an open-label phase 2a and double-blind, randomised, placebo-controlled, phase 2b, seamless, clinical trial

Rolando Ochoa-Azze, Arturo Chang Monteagudo, Yanet Climent-Ruíz, Consuelo Macías Abraham, Carmen Valenzuela‐Silva, María de los Ángeles García-García, Yanet Jerez-Barceló, Yenisey Triana-Marrero, Laura Ruiz-Villegas, Luis Dairon Rodríguez-Prieto,

The Lancet Respiratory Medicine · 2022 · 29 citations · 25 references

DOIFull text

Open access

Concepts

References

25

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial

Pedro M. Folegatti, Katie Ewer, Parvinder K. Aley et al. · The Lancet · 2020 · 2.6K citations · Full text

, , +14

Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma

Chenguang Shen, Zhaoqin Wang, Fang Zhao et al. · JAMA · 2020 · 2.4K citations · Full text

, , +16

Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial

Yanjun Zhang, Gang Zeng, Hongxing Pan et al. · The Lancet Infectious Diseases · 2020 · 1.5K citations · Full text

, , +17

Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial

Fengcai Zhu, Yu-Hua Li, Xu-Hua Guan et al. · The Lancet · 2020 · 1.5K citations · Full text

, , +17

A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2–spike protein–protein interaction

Chee Wah Tan, Wan Ni Chia, Xijian Qin et al. · Nature Biotechnology · 2020 · 1.4K citations · Full text

, , +17